XML 51 R41.htm IDEA: XBRL DOCUMENT
v3.21.1

INVESTMENTS - RELATED PARTIES (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract] |
Schedule of investments | Investments in AVLP, Alzamend Neuro, Inc. (“Alzamend”) and Ault and Company, Inc. (“Ault & Company”) at March 31, 2021 and December 31, 2020, are comprised of the following:
|  | March 31, |  |  | December 31, |
|  | 2021 |  |  | 2020 |
Investment in convertible promissory note of AVLP |  | $ | 13,924,136 |  |  | $ | 11,269,136 |
Short term advance in Alzamend |  |  | - |  |  |  | 750,000 |
Investment in convertible promissory note of Alzamend |  |  | - |  |  |  | 50,000 |
Investment in promissory note of Ault & Company |  |  | 2,500,000 |  |  |  | - |
Accrued interest in promissory notes, related parties |  |  | 2,027,557 |  |  |  | 2,026,812 |
Total investment in promissory notes, related parties – gross |  |  | 18,451,693 |  |  |  | 14,095,948 |
Less: original issue discount |  |  | (1,560,302 | ) |  |  | (3,870 | )
Less: provision for loan losses |  |  | (3,423,608 | ) |  |  | (3,423,608 | )
Total investment in promissory notes, related parties |  |  | 13,467,783 |  |  |  | 10,668,470 |
Investment in derivative instruments of AVLP |  |  | 9,516,024 |  |  |  | 4,986,552 |
Investment in common stock of AVLP |  |  | 819,324 |  |  |  | 499,588 |
Investment in common stock and warrants of Alzamend |  |  | 4,487,091 |  |  |  | 653,251 |
Investments in derivatives and common stock, related parties |  |  | 14,822,439 |  |  |  | 6,139,391 |
Total investments, related parties – net |  | $ | 28,290,222 |  |  | $ | 16,807,861 |
Investments in derivatives and common stock, related parties |  | $ | 14,822,439 |  |  | $ | 6,139,391 |
Investment in promissory notes, related parties |  |  | 13,467,783 |  |  |  | 10,668,470 |
Total investment, related parties – net |  | $ | 28,290,222 |  |  | $ | 16,807,861 |
Schedule of summarizes the changes in our investments | The following table summarizes the changes in our investments in AVLP, Alzamend and Ault & Company during the three months ended March 31, 2021:
|  |  |  |  | Investment in |  |  |  |
|  | Investment in |  |  | promissory notes |  |  | Total |
|  | warrants and |  |  | and advances |  |  | investment |
|  | common stock |  |  | of AVLP, |  |  | in AVLP, |
|  | of AVLP and |  |  | Alzamend and |  |  | Alzamend and |
|  | Alzamend |  |  | Ault & Company |  |  | Ault & Company, net |
Balance at January 1, 2021 |  | $ | 6,139,391 |  |  | $ | 10,668,470 |  |  | $ | 16,807,861 |
Investment in convertible promissory notes of AVLP |  |  | — |  |  |  | 1,094,698 |  |  |  | 1,094,698 |
Investment in convertible promissory note of Alzamend |  |  | — |  |  |  | (50,000 | ) |  |  | (50,000 | )
Investment in promissory note of Ault & Company |  |  | — |  |  |  | 2,500,000 |  |  |  | 2,500,000 |
Investment in common stock of AVLP and Alzamend |  |  | 3,046,016 |  |  |  | — |  |  |  | 3,046,016 |
Investment in warrants of Alzamend |  |  | 953,984 |  |  |  | — |  |  |  | 953,984 |
Short term advance in Alzamend |  |  | — |  |  |  | (750,000 | ) |  |  | (750,000 | )
Fair value of derivative instruments issued by AVLP |  |  | 1,560,302 |  |  |  | — |  |  |  | 1,560,302 |
Unrealized gain in derivative instruments of AVLP |  |  | 2,969,170 |  |  |  | — |  |  |  | 2,969,170 |
Unrealized loss in warrants of Alzamend |  |  | (13,086 | ) |  |  | — |  |  |  | (13,086 | )
Unrealized gain in common stock of AVLP and Alzamend |  |  | 166,662 |  |  |  | — |  |  |  | 166,662 |
Accretion of discount |  |  | — |  |  |  | 3,870 |  |  |  | 3,870 |
Accrued Interest |  |  | — |  |  |  | 745 |  |  |  | 745 |
Balance at March 31, 2021 |  | $ | 14,822,439 |  |  | $ | 13,467,783 |  |  | $ | 28,290,222 |
Schedule of black-Scholes option-pricing method | The fair value of the Company’s holdings in the AVLP warrants was estimated using the Black-Scholes option-pricing method and the following assumptions:
Exercise price |  | $0.50
Remaining contractual term (in years) |  | 1.68 — 5.0
Volatility |  | 68.7% — $104.6%
Weighted average risk free interest rate |  | 0.13% — 2.98%
Expected dividend yield |  | 0%

X
- Definition Tabular disclosure of black scholes option pricing method. + References No definition available. + Details
Name: | dpw_ScheduleOfBlackscholesOptionpricingMethod
Namespace Prefix: | dpw_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments. + References No definition available. + Details
Name: | us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the summary of investment holdings. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B) -URI http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_SummaryInvestmentHoldingsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration